Angiotensin II receptor blockers (ARBs) and cancer: Reassuring after all;Antagonistes de l'angiotensine II et cancer: Un bilan rassurant

Revue Medicale Suisse

Volumn 7, Issue 308, 2011, Pages 1757-1760

  Cassat, M ^a   Wuerzner, G ^a   Burnier, M ^a   Waeber, B ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; DISEASE ASSOCIATION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; ARTICLE; CHEMICALLY INDUCED DISORDER; META ANALYSIS (TOPIC); NEOPLASM; RISK FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN RECEPTOR ANTAGONISTS; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 80155192549     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Heinonen OP, Shapiro S, Tuominen L, et al. Reserpine use in relation to breast cancer. Lancet 1974;2: 675-7.
2. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999;83:1090-3. (Pubitemid 29162797)
3. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995;63:216-21.
4. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7. (Pubitemid 26279010)
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
6. Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence : A mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26:622-9. (Pubitemid 351354904)
7. *Grossman E, Messerli FH. Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis 2006;49: 16-25. (Pubitemid 44080802)
8. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001;22:1343-52. (Pubitemid 32737627)
9. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin- receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncology 2010;11:627-36.
10. * Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324(punctuation space)168 participants from randomised trials. Lancet Oncology 2011;12:65-82.
11. ** The ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011;29:623-35.
12. *Grossman E, Goldbourt U. Meta-analyses of antihypertensive therapy: Are some of them misleading? Curr Hypertens Rep 2001;3:381-6.
13. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179-84. (Pubitemid 28327802)
14. * Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: A review. J Hum Hypertens 2009;23:623-35.
15. *Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer? Trends Endocrinol Metab 2005; 16:293-9. (Pubitemid 41206635)
16. **Swales JD. Meta-analysis as a guide to clinical practice. J Hypertens 1993;11(Suppl.):S59-63. (Pubitemid 24024699)
17. FDA Drug Safety Communication: Ongoing safety review of the angiotensin receptor blockers and cancer. 2010. www.fda.gov/Drugs/DrugSafety/Postmarket Drug SafetyInformationforPatientsandProviders/ucm218845.htm